GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
Full year 2025 revenue of $71.7 million, up 40%Record full-year operating cash flow of $13.1 million, up 60%Board ...
Interesting Engineering on MSN
US: Lockheed’s new long-range missile for moving land, sea targets aces flight test
On March 12, 2026, Lockheed Martin successfully completed the first flight test of the ...
MLIP calculations successfully identify suitable dopants for a novel photocatalytic material, report researchers from the Institute of Science Tokyo. As demonstrated in their study, published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results